| Date | Time | Source | Headline | Symbol | Company |
| 02/23/2024 | 1:19PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:19PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:18PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:18PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:17PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:17PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:17PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:16PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:16PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:16PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:15PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:15PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:15PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:14PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:14PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:13PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:13PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:13PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/23/2024 | 1:12PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/14/2024 | 6:00PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/14/2024 | 2:23PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 01/30/2024 | 4:00PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 01/24/2024 | 4:00PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 05/30/2023 | 4:13PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 05/11/2023 | 4:24PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 05/05/2023 | 4:05PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 04/11/2023 | 6:01AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 03/31/2023 | 4:08PM | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 03/14/2023 | 4:30PM | GlobeNewswire Inc. | Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |
| 02/16/2023 | 7:30AM | GlobeNewswire Inc. | Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium | NASDAQ:BLCM | Bellicum Pharmaceuticals Inc |